Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
302 hedge funds and large institutions have $6.65B invested in Apellis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 105 increasing their positions, 91 reducing their positions, and 46 closing their positions.
46% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 46
17% more call options, than puts
Call options by funds: $111M | Put options by funds: $94.7M
15% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 91
7% more funds holding
Funds holding: 283 → 302 (+19)
3% less capital invested
Capital invested by funds: $6.82B → $6.65B (-$172M)
2.25% less ownership
Funds ownership: 96.06% → 93.81% (-2.2%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$63.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$57.4M |
| 3 |
Millennium Management
New York
|
+$49.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$48.1M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$108M |
| 2 |
Morgan Stanley
New York
|
-$93M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$88.4M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$23.1M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$23.1M |
APLS Hedge Fund Activity: Q1 2024 in Review
302 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2024, worth a combined $6.65B — down 2.5% from $6.82B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new APLS positions and 46 closed out — a net gain of 21 holders — while 105 added to existing stakes and 91 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $63.7M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $108M.
- 302 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2024, up from 283 in Q4 2023.
- Funds reported $6.65B of Apellis Pharmaceuticals stock for Q1 2024, down 2.5% quarter-over-quarter.
- 67 funds opened new Apellis Pharmaceuticals positions in Q1 2024 and 46 closed out, a net change of +21 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2024 was Deep Track Capital, an estimated $63.7M added.
- The largest Apellis Pharmaceuticals seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $108M sold.
Based on aggregated 13F filings for Q1 2024.